TriSalus Life Sciences (NASDAQ:TLSI) Earns Buy Rating from Canaccord Genuity Group

TriSalus Life Sciences (NASDAQ:TLSI)‘s stock had its “buy” rating reissued by Canaccord Genuity Group in a note issued to investors on Thursday, Benzinga reports. They currently have a $12.00 price objective on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 117.39% from the company’s current price.

Other research analysts also recently issued research reports about the stock. Canaccord Genuity Group started coverage on shares of TriSalus Life Sciences in a research note on Thursday, May 30th. They issued a “buy” rating and a $12.00 target price for the company. Jonestrading started coverage on shares of TriSalus Life Sciences in a research note on Friday, May 10th. They issued a “buy” rating and a $16.00 target price for the company.

TriSalus Life Sciences Trading Down 4.2 %

TriSalus Life Sciences stock opened at $5.52 on Thursday. TriSalus Life Sciences has a 52 week low of $3.32 and a 52 week high of $16.24. The firm’s 50-day simple moving average is $8.02 and its 200 day simple moving average is $8.74.

TriSalus Life Sciences (NASDAQ:TLSI) last announced its earnings results on Wednesday, May 15th. The company reported ($0.54) earnings per share for the quarter. The company had revenue of $6.46 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. HC Advisors LLC acquired a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 101,736 shares of the company’s stock, valued at approximately $860,000. HC Advisors LLC owned about 0.39% of TriSalus Life Sciences at the end of the most recent reporting period. 2.58% of the stock is currently owned by institutional investors.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.